Claims:

1. Use of the compound 6-(3-chloro-2-fluorobenzyl)-1-[(*2S*)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or its pharmaceutically acceptable salt for the manufacture of a medicament for increasing the bioavailability of the compound comprising administering to a patient a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof with food.

2. Use of the compound 6-(3-chloro-2-fluorobenzyl)-1-[(*2S*)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or its pharmaceutically acceptable salt for the manufacture of a medicament for increasing the absorption of the compound in a patient, comprising administering to the patient a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof with food.

3. Use of the compound 6-(3-chloro-2-fluorobenzyl)-1-[(*2S*)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or its pharmaceutically acceptable salt for the manufacture of a medicament for oral administration with food, for achieving enhanced bioavailability of the compound or the pharmaceutically acceptable salt thereof in the treatment of an integrase responsive condition, comprising administering to the patient a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof with food.

4. Use of the compound 6-(3-chloro-2-fluorobenzyl)-1-[(*2S*)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or its pharmaceutically acceptable salt for the manufacture of a medicament for oral administration with food, for achieving increased absorption of the compound or

the pharmaceutically acceptable salt thereof in the treatment of an integrase responsive condition, comprising administering to the patient a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof with food.

5. The use of any one of claims 3 or 4 wherein the integrase responsive condition is a retrovirus infection.

6. The use of claim 5 wherein the retrovirus infection is an HIV infection or AIDS.

7. The use of any one of claims 1-6, wherein said administering results in a maximum plasma concentration of the compound greater than if the compound or the pharmaceutically acceptable salt thereof was administered without food.

8. The use of any one of claims 1-6, wherein said administering results in an area under the plasma concentration time curve from time zero to infinity (AUC_{0-inf}) of the compound greater than if the compound or the pharmaceutically acceptable salt thereof was administered without food.

9. Use of the compound 6-(3-chloro-2-fluorobenzyl)-1-[(2*S*)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or its pharmaceutically acceptable salt for the manufacture of a medicament for inhibiting activity of a retrovirus integrase in a patient, comprising administering to the patient a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof with food.

10. Use of the compound 6-(3-chloro-2-fluorobenzyl)-1-[(2*S*)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or its pharmaceutically acceptable salt for the manufacture of a medicament for the treatment or prophylaxis of a retrovirus infection in a patient, comprising

administering to the patient a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof with food.

11. The use of claim 9 or 10 , wherein the retrovirus is human immunodeficiency virus (HIV).

12. The use of any one of claims 1-11 wherein the therapeutically effective amount is about 10 mg to about 2000 mg.

13. The use of claim 12 wherein the therapeutically effective amount is about 600 mg to about 1200 mg.

14. The use of any one of claims 1-13, wherein the compound or the pharmaceutically acceptable salt thereof is administered between about one hour prior to the consumption of food to about two hours after the consumption of food.

15. The use of claim14 wherein the compound or the pharmaceutically acceptable salt thereof is administered substantially at the same time as the consumption of food.

16. The use of claim 14 wherein the compound or the pharmaceutically acceptable salt thereof is administered immediately after the consumption of food and up to about one hour after consumption of the food.

17. The use of any one of claims 1-16 wherein the compound or the pharmaceutically acceptable salt thereof is administered in a pharmaceutical composition.

18. The use of claim 17, wherein the pharmaceutical composition is in a unit dosage form of a tablet.

19. The use of any one of claims 1-18 wherein the compound or the pharmaceutically acceptable salt thereof is administered orally.

20. A pharmaceutical composition comprising the compound 6-(3-chloro-2-fluorobenzyl)-1-[(*2S*)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof to be administered with food for increasing the bioavailability of the compound or the pharmaceutically acceptable salt thereof in a patient.

21. A pharmaceutical composition comprising the compound 6-(3-chloro-2-fluorobenzyl)-1-[(*2S*)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof to be administered with food for increasing the absorption of the compound or the pharmaceutically acceptable salt thereof in a patient.

22. A pharmaceutical composition comprising the compound 6-(3-chloro-2-fluorobenzyl)-1-[(*2S*)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof to be administered with food for inhibiting activity of a retrovirus integrase in a patient.

23. A pharmaceutical composition comprising the compound 6-(3-chloro-2-fluorobenzyl)-1-[(*2S*)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof to be administered with food for the treatment or prophylaxis of a retrovirus infection in a patient.

24. The pharmaceutical composition of any of claims 20-23 to be administered with ritonavir or a pharmaceutically acceptable salt thereof.

25. A kit comprising: (1) a pharmaceutical composition comprising 6-(3-chloro-2-fluorobenzyl)-1-[(*2S*)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, or a pharmaceutically acceptable salt thereof; (2) prescribing information; and (3) a container; wherein the prescribing information includes advice regarding administering 6-(3-chloro-2-fluorobenzyl)-1-[(*2S*)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof with food.

26. The kit of claim 25, wherein the prescribing information includes a description of increased bioavailability of 6-(3-chloro-2-fluorobenzyl)-1-[(*2S*)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid when administered with food than without food.

27. The kit of claim 25, wherein the prescribing information includes advice regarding administering 6-(3-chloro-2-fluorobenzyl)-1-[(*2S*)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof between about one hour prior to the consumption of food to about two hours after the consumption of food.

28. The kit of claim 25, wherein the prescribing information includes advice regarding administering 6-(3-chloro-2-fluorobenzyl)-1-[(*2S*)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof substantially at the same time as the consumption of food.

29. The kit of claim 25, wherein the prescribing information includes advice regarding administering 6-(3-chloro-2-fluorobenzyl)-1-[(*2S*)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof immediately after the consumption of food and up to about one hour after the consumption of food.

30. The kit of any one of claims 25-29 wherein the pharmaceutical composition is in a unit dosage form of a tablet.

31. The kit of any one of claims 25-29 further comprising ritonavir, or a pharmaceutically acceptable salt thereof.

Claims:

1. The compound 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, for use with food for increasing the bioavailability of the compound in a patient, the patient having taken the food during the period between 1 hour prior to the administration of the compound and 2 hours after the administration of the compound.

2. The compound 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, for use with food for increasing the absorption of the compound in a patient, the patient having taken the food during the period between 1 hour prior to the administration of the compound and 2 hours after the administration of the compound.

3. The compound 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, in a therapeutically effective amount, for use with food for the inhibition of a retrovirus integrase in a patient, the patient having taken the food during the period between 1 hour prior to the administration of the compound and 2 hours after the administration of the compound.

4. The compound of claim 3, wherein the retrovirus integrase is HIV integrase.

5. The compound 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, in a therapeutically effective amount, for use with food for the treatment or prophylaxis of a retrovirus infection in a patient, the patient having taken the food during the period between 1 hour prior to the administration of the compound and 2 hours after the administration of the compound.

6. The compound of claim 5, wherein the retrovirus infection is an HIV infection.

7. The compound of any one of claims 1 to 6, wherein the compound is used orally at a dose of 85 mg.

8. The compound of any one of claims 1 to 6, wherein the compound is used orally at a dose of 150 mg.

9. The compound of any one of claims 1 to 6, wherein the compound is used orally at a dose of 200 mg.